Close Menu

NEW YORK – Takeda said on Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of brigatinib (Alunbrig) as a first-line monotherapy for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.